Staidson BioPharm(SZ:300204) Xin Lang Cai Jing·2025-10-22 01:46Group 1 - The core point of the news is that Shutaishen's stock price increased by 6.33% to 39.33 CNY per share, with a trading volume of 492 million CNY and a turnover rate of 2.77%, resulting in a total market capitalization of 18.791 billion CNY [1] - Shutaishen (Beijing) Biopharmaceutical Co., Ltd. was established on August 16, 2002, and went public on April 15, 2011. The company primarily engages in the research, production, and sales of biological products and some chemical drugs [1] - The main revenue composition of Shutaishen includes 59.17% from injectable mouse nerve growth factor (Sutai), 33.19% from compound polyethylene glycol electrolyte powder, and 7.63% from other products [1] Group 2 - According to data from the top ten heavy stocks of funds, one fund under Great Wall Fund holds Shutaishen as a significant investment. The Great Wall Health Life Mixed A Fund (008786) held 328,900 shares in the second quarter, accounting for 3.57% of the fund's net value, ranking as the eighth largest heavy stock [2] - The Great Wall Health Life Mixed A Fund (008786) was established on August 14, 2020, with a latest scale of 343 million CNY. The fund has achieved a return of 30.31% this year, ranking 2759 out of 8160 in its category, and a return of 27.05% over the past year, ranking 2941 out of 8026 [2] - The fund manager of Great Wall Health Life Mixed A is Tan Xiaobing, who has a cumulative tenure of 9 years and 265 days. The total asset scale of the fund is 2.018 billion CNY, with the best fund return during his tenure being 162.51% and the worst being -33.94% [3]